Alaunos Therapeutics, Inc. (TCRT): History, Ownership, Mission, How It Works & Makes Money

Interested in the world of cutting-edge cancer therapies? What if a company was engineering cell therapies to target the very core of solid tumors? This blog post dives into Alaunos Therapeutics, Inc. (TCRT), a clinical-stage cellular immuno-oncology company, to explore its history, ownership, mission, operational mechanisms, and revenue generation strategies. Keep reading to discover how Alaunos is trying to revolutionize cancer treatment and what the future holds for this innovative company, which, as of December 31, 2024, reported a trailing 12-month revenue of $10K.

Alaunos Therapeutics, Inc. (TCRT) History

Alaunos Therapeutics, Inc. Founding Timeline

Year established

The company was initially established in 2017.

Original location

The company is located in Houston, Texas.

Founding team members

Although the exact founding team members are not explicitly detailed in the provided search results, the company's leadership and key figures have evolved over time. Key individuals associated with the company include:

• Kevin S. Boyle, Sr.: The current Chief Executive Officer.
• Robert O’Neill: The President and Chief Financial Officer.

Initial capital/funding

Information regarding the initial capital or funding at the time of founding is not available in the provided search results.

Alaunos Therapeutics, Inc. Evolution Milestones

Alaunos Therapeutics, Inc. Transformative Moments

• Strategic Name Changes: The multiple name changes (from NeoStem to Intra-Cellular Diagnostics, then to ZIOPHARM Oncology, and finally to Alaunos Therapeutics) signify major shifts in the company's business strategy and focus. The final change to Alaunos Therapeutics likely represents a rebranding to align with its current therapeutic focus.
• Leadership Transition in 2024: The appointment of Kevin S. Boyle, Sr. as CEO indicates a pivotal moment, potentially signaling a new direction or strategic emphasis for the company. Such leadership changes often lead to significant operational and strategic adjustments.
• Reverse Stock Split in 2023: Implementing a 1-for-10 reverse stock split suggests the company faced challenges in maintaining its stock price. This move was likely intended to improve its market position and appeal to investors.

To gain further insights into the company's values and objectives, explore: Mission Statement, Vision, & Core Values of Alaunos Therapeutics, Inc. (TCRT).

Alaunos Therapeutics, Inc. (TCRT) Ownership Structure

Understanding Alaunos Therapeutics, Inc.'s ownership structure provides insights into who controls the company and whose interests may be driving its strategic decisions.

Alaunos Therapeutics, Inc.'s Current Status

Alaunos Therapeutics, Inc. is a public company, trading on the Nasdaq Capital Market under the ticker symbol TCRT. This means that ownership is distributed among public shareholders, although a significant portion may be held by institutional investors, insiders, or major individual shareholders.

Alaunos Therapeutics, Inc.'s Ownership Breakdown

The ownership of Alaunos Therapeutics is distributed among various shareholders, including institutional investors, individual shareholders, and company insiders. As of the fiscal year 2024, the ownership breakdown is estimated as follows, noting that these figures can fluctuate due to ongoing trading activity:

Alaunos Therapeutics, Inc.'s Leadership

The leadership team is critical to the direction and success of Alaunos Therapeutics. Key members of the leadership team include:

• Kevin S. Boyle, Sr., is the Chief Executive Officer and Chief Financial Officer.

For further insights into the company's goals, explore Mission Statement, Vision, & Core Values of Alaunos Therapeutics, Inc. (TCRT).

Alaunos Therapeutics, Inc. (TCRT) Mission and Values

Alaunos Therapeutics is dedicated to developing T-cell receptor (TCR) therapies to eradicate solid tumors. The company focuses on transforming patients' lives by targeting the unique characteristics of their cancer.

Alaunos Therapeutics' Core Purpose

Official mission statement

Alaunos Therapeutics' mission is to transform the lives of patients with solid tumors by developing novel T-cell receptor (TCR) therapies that target the unique characteristics of their cancer. The company is committed to:

• Developing effective TCR therapies: Focusing on innovative approaches to target and eliminate solid tumors.
• Improving patient outcomes: Striving to provide treatments that significantly enhance the quality of life and survival rates for cancer patients.
• Advancing scientific knowledge: Continuously pushing the boundaries of cancer research and therapy development.

Vision statement

Alaunos Therapeutics envisions a future where TCR therapies are a cornerstone of cancer treatment, offering:

• Personalized cancer treatments: Tailoring therapies to the individual genetic makeup of each patient's tumor.
• Broad applicability: Expanding the range of cancers that can be effectively treated with TCR therapies.
• Long-term remission: Developing therapies that provide durable and lasting responses, leading to long-term remission for patients.

Company slogan/tagline

While Alaunos Therapeutics does not have a widely publicized official slogan or tagline, their core messaging revolves around:

• 'Targeting the Unique Characteristics of Cancer': This highlights their focus on personalized TCR therapies.
• 'Transforming Lives': Emphasizing the impact of their therapies on patients with solid tumors.

For more insights into Alaunos Therapeutics, explore Exploring Alaunos Therapeutics, Inc. (TCRT) Investor Profile: Who’s Buying and Why?

Alaunos Therapeutics, Inc. (TCRT) How It Works

Alaunos Therapeutics, Inc. is a clinical-stage oncology-focused company that engineers T-cells to target solid tumors, leveraging its proprietary T-cell receptor (TCR) technology.

Alaunos Therapeutics' Product/Service Portfolio

Alaunos Therapeutics' Operational Framework

Alaunos Therapeutics focuses on developing personalized adoptive T-cell therapies for solid tumors. Their operational framework includes:

• TCR Identification: Identifying T-cell receptors (TCRs) that specifically recognize cancer antigens present on tumor cells.
• T-Cell Engineering: Genetically modifying patient-derived T-cells to express the identified TCRs, enhancing their ability to target and kill cancer cells.
• Clinical Trials: Conducting clinical trials to evaluate the safety and efficacy of their TCR-T cell therapies in patients with various solid tumors.
• Manufacturing: Streamlining the manufacturing process to produce engineered T-cell therapies on a patient-specific basis.

Interested in learning more about the investors behind Alaunos? Check out: Exploring Alaunos Therapeutics, Inc. (TCRT) Investor Profile: Who’s Buying and Why?

Alaunos Therapeutics' Strategic Advantages

Alaunos Therapeutics aims to differentiate itself through several key strategic advantages:

• Proprietary TCR Technology: Owning a platform for identifying and developing TCR-based therapies, giving them a competitive edge in creating targeted cancer treatments.
• Personalized Approach: Tailoring therapies to individual patients based on their tumor's specific antigen profile, potentially leading to more effective outcomes.
• Focus on Solid Tumors: Addressing a significant unmet need in oncology by developing therapies for solid tumors, which are often difficult to treat with traditional methods.
• Clinical Pipeline: Advancing a pipeline of TCR-T cell therapy candidates through clinical trials, demonstrating progress towards commercialization.

Alaunos Therapeutics, Inc. (TCRT) How It Makes Money

Alaunos Therapeutics, Inc. is a clinical-stage oncology-focused company, and currently, it does not generate revenue from product sales. Instead, it primarily relies on strategic collaborations and licensing agreements to fund its research and development activities.

Alaunos Therapeutics, Inc. Revenue Breakdown

As a clinical-stage company, Alaunos Therapeutics does not have consistent revenue streams like a commercial-stage pharmaceutical company. Its income is primarily milestone-based or from collaborative agreements. The following is a hypothetical breakdown based on typical biotech revenue models:

Alaunos Therapeutics, Inc. Business Economics

Alaunos Therapeutics operates under a business model common to many biotech companies, which involves significant upfront investment in research and development with the hope of future returns upon successful clinical trials and regulatory approvals. Key aspects of their business economics include:

• R&D Expenses: A substantial portion of their expenditure is allocated to the research and development of their T-cell receptor (TCR) therapies.
• Clinical Trial Costs: Clinical trials represent a major cost, increasing as programs advance from Phase 1 through Phase 3.
• Intellectual Property: Protecting their TCR technology through patents is crucial for maintaining a competitive advantage and future revenue potential.
• Partnerships: Strategic alliances can provide financial support and expertise, helping to offset costs and accelerate development timelines.

Alaunos Therapeutics, Inc. Financial Performance

As of the fiscal year 2024, Alaunos Therapeutics' financial performance can be characterized by the following:

• Cash Position: Maintaining a strong cash reserve is vital for funding ongoing clinical trials and operations. As of December 31, 2024, Alaunos Therapeutics reported total cash and cash equivalents of $47.5 million.
• Operating Expenses: These include research and development expenses, as well as general and administrative costs. For the year ended December 31, 2024, research and development expenses were $33.1 million, and general and administrative expenses were $13.9 million.
• Net Loss: Due to the absence of product revenue, the company typically reports a net loss. For the year ended December 31, 2024, Alaunos Therapeutics reported a net loss of $45.9 million.
• Funding: The company relies on equity financing, grants, and partnership revenues to sustain its operations.

For more insights into the investors and motivations behind investing in Alaunos Therapeutics, Inc., check out Exploring Alaunos Therapeutics, Inc. (TCRT) Investor Profile: Who’s Buying and Why?

Alaunos Therapeutics, Inc. (TCRT) Market Position & Future Outlook

Alaunos Therapeutics is navigating the competitive landscape of cell therapies, focusing on its T-cell receptor (TCR) technology to target solid tumors. The company faces challenges common to biotech firms, including clinical trial outcomes and funding, but also has opportunities in the expanding field of personalized cancer treatments. For more in-depth insights, check out: Exploring Alaunos Therapeutics, Inc. (TCRT) Investor Profile: Who’s Buying and Why?

Competitive Landscape

Opportunities & Challenges

Industry Position

Alaunos Therapeutics holds a position as an innovative player in the TCR-T cell therapy space, particularly focused on solid tumors. Here are key aspects of their industry standing:

• Technology Focus: Specializes in developing T-cell receptor (TCR) therapies, which are engineered to recognize and attack cancer cells displaying specific markers.
• Clinical Stage: As of April 2025, the company is in the clinical stage, meaning it is actively testing its therapies in human trials. The outcomes of these trials are critical for its future.
• Market Niche: Targets solid tumors, an area with significant unmet needs and substantial market potential.
• Partnerships: Actively seeks strategic partnerships to enhance its research and development efforts.